Drug Trial Radar · NCT00003725
Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer
Last checked: Nov 20, 2026Latest source record: Nov 6, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
300
Planned (sponsor's estimate)
Start
Dec 1996
Primary completion
Not stated
Sponsor
- Lead sponsor
- Anthra PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jul 22, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Transurethral resection is a less invasive type of surgery for bladder cancer and may have fewer side effects and improve recovery. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether transurethral resection plus AD 32 is more effective than transurethral resection alone for bladder cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of transurethral resection surgery followed by AD 32 with that of transurethral resection alone in treating patients who have newly diagnosed or recurrent bladder cancer.
Conditions
- Bladder Cancer
Interventions
valrubicinDrug
conventional surgeryProcedure
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
53 sites in 2 countries. Site status is shown where the registry gives one.
Urology Associates
Birmingham, Alabama
Urology Associates, Ltd.
Phoenix, Arizona
University of California San Diego Cancer Center
La Jolla, California
San Diego Urology Center
La Mesa, California
Hillcrest Urological Medical Group
San Diego, California
San Diego Urology Center
San Diego, California
UCSF Cancer Center and Cancer Research Institute
San Francisco, California
Santa Monica Urologic Medical Group
Santa Monica, California
Western Urological Associates
Van Nuys, California
Urology Specialists, P.C.
Waterbury, Connecticut
George Washington University Hospital
Washington D.C., District of Columbia
Atlantic Urological Associates
Daytona Beach, Florida
University of Florida - Gainesville
Gainesville, Florida
Sylvester Cancer Center, University of Miami
Miami, Florida
Urology Care - South
Miami, Florida
Urology Health Center
New Port Richey, Florida
Office of Ira W. Klimberg
Ocala, Florida
Urology Treatment Center
Sarasota, Florida
Georgia Urology
Atlanta, Georgia
Affliated Urology
Chicago, Illinois
University of Chicago Cancer Research Center
Chicago, Illinois
Evanston Northwestern Healthcare
Evanston, Illinois
Clinic of Urologic Wellness
Lexington, Kentucky
Louisiana State University Health Sciences Center - Shreveport
Shreveport, Louisiana
Cambridge Urological Associates, Inc.
Cambridge, Massachusetts
Michigan Institute of Urology
Detroit, Michigan
Mississippi Urology Clinic, P.A.
Jackson, Mississippi
Urology Center
Omaha, Nebraska
Sheldon Freedman Ltd.
Las Vegas, Nevada
Desert Urology
North Las Vegas, Nevada
Norris Cotton Cancer Center
Lebanon, New Hampshire
Veterans Affairs Medical Center - East Orange
East Orange, New Jersey
Office of John Byrne
New Rochelle, New York
Mount Sinai Medical Center, NY
New York, New York
Herbert Irving Comprehensive Cancer Center
New York, New York
Wake Urological Associates
Raleigh, North Carolina
Department of Urology and Urologic Oncology
Columbus, Ohio
Oregon Cancer Center at Oregon Health Sciences University
Portland, Oregon
Urology Clinic, P.C.
Portland, Oregon
Office of Jeffrey K. Cohen
Pittsburgh, Pennsylvania
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.